Sebastian Fuchs, Merck KGaA, Darmstadt
At Merck Healthcare, we are working on the acceleration of the Design-Make-Test-Analyze (DMTA) cycle through comprehensive digitalization and automation. We highlight the use of Genedata Screener for automated data analysis, ensuring superior quality control of assay data. By fully automating small-scale assays, we enhance the DMTA process, from test ordering to data upload, significantly minimizing human error and increasing throughput.
Our automation platform comprehensively includes biochemical assays, automating the thawing and preparation of reagents and enzymes. Separately, for cellular processes, we automate cell thawing, mixing, and seeding into 1536-well plates, supporting both high-throughput screening (HTS) and small-scale experiments.
